The QualityStocks Daily Wednesday, July 3rd, 2019

Today's Top 3 Investment Newsletters

Penny Stock Titans (VEII) +573.08%

SmallCapRelations (RNWR) +77.78%

QualityStocks (RCCMF) +59.05%

The QualityStocks Daily Stock List

TerrAscend Corp. (TRSSF)

Street Signals, Financial Content, CannabisMarketCap, Market Screener, The Seed Investor, Wallet Investor, Midas Letter, Stockhouse, New Cannabis Ventures, Hottest Stock Picks, Profit Confidential, GuruFocus, Small Cap Power, Energy and Capital, MicroCapDaily, Trading View, Barchart, Seeking Alpha, The Street, and MarketWatch reported previously on TerrAscend Corp. (TRSSF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

TerrAscend Corp. is a biopharmaceutical and wellness company based in Mississauga, Ontario. Its dedication is to quality products, brands, and services for the global cannabinoid market. TerrAscend participates in the medical and legal adult-use market in Canada and in U.S. States where cannabis has been legalized for therapeutic or adult-use. The Company lists on the OTC Markets Group’s OTCQX.

TerrAscend operates a number of synergistic businesses. These include Arise Bioscience, Inc., a manufacturer and distributor of hemp-derived products, Ascendant Laboratories, Inc., a biotechnology and licensing Company dedicated to the continuous improvement of cannabinoid expressing plants, and Solace RX, Inc., a proposed drug preparation premises focused on the development of novel formulations and dosage forms. TerrAscend’s brands include Haven St. Premium Cannabis; and Knüba Naturals, which is a line of premium cannabis products.

The Company has its facility built to GMP requirements. The facility is 67,300 sq. ft., located in Mississauga. It features premium hydroponic cultivation and products are lab tested to the highest standards. The facility has sterile and non-sterile drug compounding capabilities. TerrAscend announced in January 2019 the closing of the previously reported asset acquisition of Grander Distribution, LLC. Grander is an industry leader in the production and distribution of inventive hemp-derived wellness products. Grander’s whole-plant hemp extract products are made in the U.S. and are available for sale in roughly 10,000 retail locations worldwide.

TerrAscend has signed definitive securities purchase agreements facilitating a significant investment in three entities in California operating the award-winning retail dispensary brand known as "The Apothecarium". Moreover, the purchase agreements include the acquisitions of a vertically integrated operation in Nevada with cultivation, edible manufacturing and an Apothecarium retail location, and also Valhalla Confections, a provider of top premium edible products.

Recently, TerrAscend reported financial results for Q1 ended March 31, 2019. The Company generated revenue of $14.6 million, up from $5.0 million in Q4 of 2018. TerrAscend did not have Revenue in the comparable Q1 of 2018. Adjusted EBITDA loss (non-GAAP measure) was $7.2 million for Q1 of 2019, versus a loss of $7.1 million in Q4 of 2018 and a loss $1.6 million in the comparable Q1 of 2018.

TerrAscend has closed a series of transactions to acquire the California operations of the award-winning retail dispensary brand called "The Apothecarium" for consideration consisting of US$36.8 million in cash and proportionate voting shares in the equity of TerrAscend equivalent to 6.7mm common shares of the Company. TerrAscend plans to close the full acquisition of the Apothecarium's California entities and also the acquisition of The Apothecarium's Nevada entities following receipt of final regulatory approvals, expected in the second or third quarter of 2019.

TerrAscend Corp. (TRSSF), closed Wednesday's trading session at $5.00, off by 1.5748%, on 30,939 volume with 53 trades. The average volume for the last 3 months is 49,096 and the stock's 52-week low/high is $2.95000004/$10.4404001.

chart

Enthusiast Gaming Holdings, Inc. (EGHIF)

Street Signals, OTC Markets, Wallet Investor, MicroSmallCap, Trading View, GlobeNewswire, Stockhouse, InvestorsHub, Seeking Alpha, Stockwatch, The Street, Market Screener, and GuruFocus reported previously on Enthusiast Gaming Holdings, Inc. (EGHIF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Enthusiast Gaming Holdings, Inc. is the fastest-growing online community of video gamers. The Company has a platform of greater than 80 owned and affiliated websites. At present, it reaches more than 75 million monthly visitors with its unique and curated content and over 50 million YouTube visitors. Enthusiast Gaming Holdings lists on the OTC Markets Group’s OTCQB. Established in 2014, the Company is based in Toronto, Ontario.

Enthusiast Gaming focuses on building the largest network of authentic gaming enthusiasts, through events, original content, as well as advertising. In addition, it owns and operates Canada’s largest gaming expo, Enthusiast Gaming Live Expo, EGLX, (eglx.ca) with over 55,000 people attending in 2018. Enthusiast Gaming’s innovative growth strategy adds to the website monetization potential that powers its platforms and partners. The Company is currently generating over one billion ad requests per week by way of Enthusiast Gaming Media and affiliated partners.

Last week, Enthusiast Gaming announced that Luminosity Gaming officially entered the popular Ubisoft video game title, Rainbow Six Siege. Luminosity has signed "92 Dream Team," the current first-place team in the North American division of the Rainbow Six Pro League. Luminosity is one of the largest and most successful esports organizations in North America. The Rainbow Six Pro League is the most prestigious R6S competition in the world.

This announcement aligns well with Enthusiast Gaming’s recent partnership with Ubisoft Canada to host the Rainbow Six Canada Nationals and bring the Ubisoft show floor activation to Enthusiast Gaming Live Expo (EGLX) in October 2019. On May 31, 2019, Enthusiast Gaming announced a merger with Luminosity and Aquilini GameCo., to create the largest vertically integrated gaming and esports company in the world.

Menashe Kestenbaum, Chief Executive Officer of Enthusiast Gamin, said, “We continue to realize synergies between Enthusiast and Luminosity which will be beneficial for the growth and success of the merged entity. The ability to attract top talent and leverage partnerships across the entire network will help increase reach and monetization opportunities.”

Enthusiast Gaming Holdings, Inc. (EGHIF), closed Wednesday's trading session at $1.15413, up 2.8178%, on 105,801 volume with 59 trades. The average volume for the last 3 months is 18,612 and the stock's 52-week low/high is $0.611699998/$1.38999998.

chart

China Health Industries Holdings, Inc. (CHHE)

The Hot Penny Stocks, StockEarnings, Zacks, OTC Markets, Simply Wall St, Stockhouse, Wallet Investor, YCharts, Hot OTC Stocks, Wallmine, InvestorsHub, Marketwired, Proactive Investors, and GuruFocus reported previously on China Health Industries Holdings, Inc. (CHHE), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

China Health Industries Holdings, Inc. is a holding company vertically integrated with the operations in its subsidiaries in China. The Company specializes in research and development (R&D), production, marketing and distribution of hemp derivative products, medicines and health supplement products. OTCQB-listed, China Health has its corporate office in Harbin, China.

The Company’s intention is to market much of its product line covering all of China and also overseas countries. As an initial step toward implementing its business plan, China Health Industries strategically transferred its business to production, sales and R&D of Hemp-based products in 2018. It is working to establish sales centers and chain-stores to connect consumers closely with its products.

China Health Industries owns GMP certified plants and facilities. The Company manufactures 21 CFDA approved medicines and 14 health supplement products covering five kinds of dosage forms. These include soft capsule, hard capsule, tablet, granule, and oral liquid. Its product series encompass hemp derivative foods, hemp derivative medicines, externally used medicines and health foods. These products address important major markets. These include women’s products, geriatric products, children’s products and other key market sectors.

China Health Industries announced in December of 2018 it completed the strategic transformation from being a traditional health supplement products manufacturer to a hemp derivative products pioneer. Its hemp derivative products have been launched into the Chinese market since May of 2018. This includes Hemp Oil, Hemp Protein Powder, Hemp Polypeptide and Hemp Cosmetics.

Recently, China Health Industries announced the financial results for its Q3 ended March 31, 2019. Mr. Xin Sun, Chief Executive Officer and Chairman of China Health Industries, said, "We are pleased to report our financial results for the third quarter of our 2019 fiscal year. Our revenue increased by 43.18 percent for the three months ended March 31, 2019 compared to the same period of the previous year as we continue to develop, manufacture and distribute new hemp derivative products. We have applied new Cannabidiol patents in 2019, and we will launch many more hemp derivative products into the market."

China Health Industries Holdings, Inc. (CHHE), closed Wednesday's trading session at $0.75, even for the day, on 1,000 volume. The average volume for the last 3 months is 1,726 and the stock's 52-week low/high is $0.301999986/$1.75.

chart

Comepay, Inc. (CMPY)

Business Insider, InvestorsHub, MarketWatch, Nasdaq, and Barchart reported earlier on Comepay, Inc. (CMPY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Comepay, Inc. provides Internet acquiring and support services. The Company also engages in facilitating instant payments and internet based payment transactions through kiosks, mobile interfaces, and Web-based applications. The Comepay group of companies includes Comepay, RP Systems, M-NN LLC, and Chek-Online. Comepay is based in Vaughan, Ontario.

The Company also leases and sells cash registers and point of sale (POS) systems. This includes its recently developed proprietary multifunctional smart POS fiscal cash register system. Comepay processes greater than 4.7 million customer payments monthly. Currently, the Company has more than 12,700 kiosks throughout Russia.

The above-mentioned companies are now focusing their planned business expansion on the smart POS fiscal cash register system "Cassatka". This is to help businesses comply with Russian taxation legislation, 54-FZ, which required 1.2 million businesses in fiscal 2018, and a further 1.4 million businesses in fiscal 2019 to install new, federally compliant on-line cash registers.

The Cassatka is Comepay's multifunctional smart POS online fiscal cash register. Cassatka can process payments and meet fiscal data storage requirements for participating businesses. Cassatka is a convenient and cost competitive solution for businesses to meet the new federal taxation requirements in Russia.

As the companies expand their business model, Comepay expects to offer blockchain acquiring services and to accept payments in numerous crypto currencies on the Cassatka. The Comepay group of companies currently earn revenue from a variety of channels. These include fee-based commissions on payment processing for cash and debit card payments, software licensing, kiosk placement fees and other rental fees for cash registers and associated equipment.

This week, Comepay announced that Chek-online LLC, a subsidiary of Comepay, and the manufacturer of the smart terminal and fiscal cash register line “Cassatka”, started a cooperative project with Zolotaya Korona, the operator of “KoronaPay”, the largest payment system in Russia offering simple and convenient cash money transfer services used by millions of customers in Russia, CIS and globally to integrate use of Zolotaya Korona transport cards with the Cassatka smart terminal, making the transport cards fully compliant with recent Russian tax legislation.

The ready-made technology offered by the Zolotaya Korona system allows for loading cash onto all types of transport and social cards, including bank-transport cards, freight-discount cards, corporate transport cards, travel cards for single or multiple trips, holiday transport cards, and cards with flexible or discounted travel rates depending on the recharge amount.

Comepay, Inc. (CMPY), closed Wednesday's trading session at $1.75, off by 2.2346%, on 2,015 volume with 18 trades. The average volume for the last 3 months is 16,130 and the stock's 52-week low/high is $0.319999992/$5.25.

chart

Leagold Mining Corporation (LMCNF)

OTC Markets, Northern Miner, Baystreet, StreetWise Reports, Stockhouse, News to Watch, Ceo.ca, Metals News, InvestorsHub, 4-Traders, and StockInvest.us reported previously on Leagold Mining Corporation (LMCNF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Leagold Mining Corporation is a mid-tier gold producer. It focuses on opportunities in Latin America. The Company formerly went by the name HTI Ventures Corp. It changed its name to Leagold Mining Corporation in August of 2016. Leagold Mining is headquartered in Vancouver, British Columbia. The Company lists on OTC Markets’ OTCQX.

Leagold owns four operating gold mines in Mexico and Brazil. In addition, the Company has an expansion opportunity in Mexico and a near-term gold mine restart project in Brazil. Leagold Mining has an inventory of 7.1 million ounces of gold reserves from which to grow. Its operating mines are Los Filos, RDM, Fazenda, and Pilar. Its development projects are the Los Filos expansion and Santa Luz.

The expectation is that Leagold Mining’s four gold mines in Mexico and Brazil will collectively produce 380,000-420,000 oz gold this year at an all-in sustaining cost (AISC) of $920-970/oz. In 2018, the Company produced 302,550 oz gold – in line with guidance of 295,000- 305,000 oz.

Leagold Mining announced this past March that it filed the report entitled "Independent Technical Report for the Los Filos Mine Complex, Mexico " that presents the results of the Expansion Feasibility Study under its profile on SEDAR at www.sedar.com. The Expansion Feasibility Study was prepared by independent consultants.

The Expansion Feasibility Study incorporates the potential for development of the Bermejal underground mine, enlarging the Los Filos open pit, re-phasing of the Bermejal open pit into two distinct sections (Bermejal and Guadalupe), and building a carbon-in-leach (CIL) processing facility to complement the existing heap leach facilities. A highlight of the Expansion Feasibility Study is gold production of 3.2 million ounces (Moz) over a 10-year mine life (2019 to 2028) at an average AISC of $740/oz.

Last week, Leagold Mining announced it completed the earlier announced debt refinancing with a syndicate of lenders, which includes a $200 million term loan and a $200 million revolving credit facility. The loans have been used to replace $238 million of existing short-term debt. Additionally, they will provide new financing for Leagold Mining’s growth via the phased expansion of the Los Filos mine complex and the construction of the Santa Luz project.

The expansion of the Los Filos mine complex has been organized into three distinct projects. These will have staggered start dates. The CIL plant construction is now scheduled to commence in mid-2020, after significant progress with accessing ore at the Bermejal underground and Guadalupe open pit is achieved. The development of Santa Luz is scheduled for Q1 2021, after considerable completion of all elements of the Los Filos expansion. The Company decided to proceed with the Los Filos expansion, when the refinancing closes, and to start construction of the Santa Luz project in Q1 2021.

Leagold Mining Corporation (LMCNF), closed Wednesday's trading session at $1.56, up 1.9208%, on 30,250 volume with 19 trades. The average volume for the last 3 months is 60,215 and the stock's 52-week low/high is $0.949999988/$2.05999994.

chart

Tel-Instrument Electronics Corp. (TIKK)

Stock Twits, Zacks, Marketbeat, Investors Hangout, Trading View, Simply Wall St, Infront Analytics, Business Wire, Whale Wisdom, and Market Screener reported previously on Tel-Instrument Electronics Corp. (TIKK), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Tel-Instrument Electronics Corp. is the industry leader in developing and producing field-tested, robust avionic flight line and bench test sets for demanding military and commercial customers. It designs, manufactures, and sells avionics test and measurement solutions. These are for the commercial air transport, general aviation, and government/military aerospace and defense markets in the U.S. and internationally. Established in 1947, Tel-Instrument Electronics is headquartered in East Rutherford, New Jersey.

Tel-Instrument Electronics uses a large network of Approved Dealers globally for sales and support. The Company operates in two segments, Avionics Government and Avionics Commercial. It operates in the Aerospace & Defense industry in the Industrials sector. Tel-Instrument Electronics is ISO-9001:2015 quality certified. The Company is compliant to ESD standard ANSI/ESD S20.20 and its products have received CE certification for sales into Europe.

The Company’s products have led the avionics support equipment industry to higher levels of integration through combining more test functions into a single unit. This decreases customer acquisition, training, and life-cycle support costs. Tel-Instrument Electronics provides instruments to test, measure, calibrate, and repair a spectrum of airborne navigation and communication equipment. In addition, its products include TS-4530A, an identification friend or foe test set; T-47/M5, a dual crypto test set; and AN/ARM-206, an intermediate level TACAN test set.

Tel-Instrument Electronics also offers AN/USM-708 and AN/USM-719, which are communications/navigation radio frequency avionics flight line testers; TR-220, a test set that provides test capability for traffic and collision avoidance systems (TCAS), distance measuring equipment, and transponders; TR-36, a commercial navigation and communication test set that provide ramp testing; and TR-420, a ramp test set to test the operation of transponders and interrogators.

The Company also provides multifunction ramp test sets under the T-47NC, T-47NH, and T-47G names; TR-100AF, a rugged ramp test used to verify airborne TACAN equipment; and AN/APM-480A, a transponder, interrogator, and TCAS test set.

This week, Tel-Instrument Electronics reported Net Income of $203,038 on Revenues of $12,116,050 million for the fiscal year ended March 31, 2019. Annual Revenues increased 21 percent to $12.1 million with $8.1 million recorded in the second half of the fiscal year. Gross Margins improved to 45 percent in comparison to 31 percent in the year ago period because of manufacturing efficiencies and cost controls.

Tel-Instrument Electronics Corp. (TIKK), closed Wednesday's trading session at $2.50, even for the day, on 8,200 volume with 10 trades. The average volume for the last 3 months is 2,333 and the stock's 52-week low/high is $2.25/$6.00.

chart

TILT Holdings, Inc. (SVVTF)

Stock News Now, OTCtipReporter, PennyStockScholar, Profitable Trader Authority, SmallCapVoice, Penny Stock 101, CFN Media Group, Wealth Daily, Cannabis Financial Network News, Promotion Stock Secrets, Stock Commander, Damn Good Penny Picks, Penny Picks, OTCJournal, and StockRockandRoll reported earlier on TILT Holdings, Inc. (SVVTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

TILT Holdings, Inc. is a top business to business (B2B) company in the cannabis industry. The majority of its products are customized to client specifications and branding, all enabling them to operate their businesses more efficiently and connect with their customers more effectively. TILT centers on the production and delivering genetically researched cannabis products via the wholesale market in partnership with retail operators; and the provision of software and services that help retail partners in connecting with retail customers with knowledge based promotional activities. TILT Holdings lists on the OTCQB. TILT is headquartered in Cambridge, Massachusetts, with offices throughout the U.S., Toronto and London.

TILT is organized in three main business units, Cultivation & Production, Software & Services and Consumer Devices & Packaged Goods. The Company’s vision is to provide value to all cannabis retailers through software, infrastructure, access to capital, and more. TILT offers extensive operations and software solutions at each point in the supply chain. This is from vertically integrated operations to pioneering genetics and business technology solutions. TILT serves more than 1,000 dispensaries throughout the U.S. and Canada.

TILT Holdings earlier announced that Jupiter Research, LLC has further expanded distribution of its proprietary, high-performance technologies in California via its integration with TILT’s software and supply chain services. The expansion allows Jupiter Research to establish a physical presence with increased geographic reach throughout California, enabling TILT to develop stronger customer relationships and deliver Jupiter products to B2B (Business-to-Business) customers faster. Jupiter Research is a leader in inhalation and vaporization technology and is a wholly-owned subsidiary of TILT Holdings.

Recently, TILT Holdings announced that its subsidiary, Blackbird Logistics Corporation, has delivered cannabis products to every licensed cannabis dispensary in California and Nevada, totaling greater than 600 retail locations. The announcement marks Blackbird’s growth into the region’s leading distributor of its kind.

After launching the business in Nevada in 2015 and growing to be the largest distributor in the State, Blackbird Logistics expanded to California at the beginning of 2018. Since then, Blackbird has grown to employ over 200 people and delivers for some of the most recognized brands in cannabis, servicing over 200 licensed cultivators, manufacturers, and producers in California. Blackbird Logistics operates three licensed facilities throughout the State. It plans to triple its distribution square footage this year.

Last week, TILT Holdings announced that its shares have been included in the Horizons US Marijuana Index ETF (HMUS/HMUS.U). The Horizons US Marijuana Index ETF seeks to replicate, to the extent possible, the performance of the US Marijuana Companies Index, net of expenses.

TILT Holdings, Inc. (SVVTF), closed Wednesday's trading session at $0.90, off by 3.059%, on 193,491 volume with 152 trades. The average volume for the last 3 months is 5963,953 and the stock's 52-week low/high is $0.838999986/$3.00.

chart

Nippon Dragon Resources, Inc. (RCCMF)

OTC Markets Group, InvestorsHub, MarketWatch, Investor Place, Stock Gumshoe, Zacks, Dividend Investor, Morningstar, Talk Markets, Streetwise Reports, 4-Traders, Wallet Investor, GuruFoucs, YCharts, and Stockhouse reported previously on Nippon Dragon Resources, Inc. (RCCMF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Nippon Dragon Resources, Inc. is a hybrid mining & technology enterprise listed on the OTC Markets. The Company has high potential and advanced stage mining assets combined with an innovative and exclusive green mining method. Nippon is active in the exploration and development of gold resources in the Province of Quebec. Nippon’s flagship gold property is Rocmec 1. Nippon Dragon Resources is headquartered in Brossard, Quebec.

The Company has its Thermal Fragmentation mining method. This mining method uses heat to 'spall' high-grade veins. This considerably lessens the use of explosives. The method only extracts the mineralized ore with minimal dilution. The extraction process allows thermal fragmentation with an accuracy of 2 cm to quickly extract any type of hard rock up to 110 cm wide. The thermal unit can be set up to extract a specific corridor. Thermal Fragmentation could be used as a stand-alone method or as a first-rate complement to any conventional hard rock mining operation.

In June of last year, Nippon Dragon Resources announced that following the sale of a Thermal Fragmentation Unit to its client, Metalfer Mining D.O.O, the Unit was shipped, received, inspected by border authorities and released to the client. Nippon’s technical team performed its customary four week orientation, training, and implementation programme of its thermal fragmentation mining method at Metalfer’s mining site in the Majdan Mountain district of Serbia.

Nippon Dragon Resources has a strategic partnership agreement with Val d’Or Resources (VOR). This partnership agreement will enhance Nippon Dragon’s position as an industry leader with its exclusive and patented Thermal Fragmentation technology. Through the creation of a new entity, Rocmec Gold, Inc., the new partnership is anticipated to substantially expand Nippon Dragon’s reach within Canada and other important markets.

Nippon’s flagship Rocmec 1 is a fully permitted project in Quebec. The project includes a 100-meter deep, two-compartment shaft, and an 844 meters decline, allowing access to four levels (50, 90, 110 and 130 meters).

Additionally, Nippon has its Denain Project. This project covers two contiguous mining properties (Venpar and Vauquelin) totaling 24 mining titles. The Denain Project is about 60 km east of Val d'Or, Quebec. At the end of August 2018, Nippon Dragon Resources announced that it signed a joint venture (JV) agreement with a group of private investors to develop its Denain gold property.

In addition, Nippon has its Courville-Maruska exploration property in Courville Township, roughly 32 kilometers’ northeast of Val-d'Or, Quebec. The property consists of 20 mining claims covering an area of around 800 hectares. The property is on a gold-bearing quartz vein system.

Nippon Dragon Resources, Inc. (RCCMF), closed Wednesday's trading session at $0.024, up 59.0457%, on 15,000 volume with 2 trades. The average volume for the last 3 months is 4,872 and the stock's 52-week low/high is $0.002/$0.028999999.

chart

MYM Nutraceuticals, Inc. (MYMMF)

Stockhouse, MarketWatch, OTC Markets, Barchart, Investing, InvestorsHub, and Market News Updates reported on MYM Nutraceuticals, Inc. (MYMMF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

MYM Nutraceuticals, Inc. focuses on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. The Company is looking to acquire complementary businesses and assets in the technology, nutraceuticals, and CBD sectors. MYM is the sole owner of CBD brands HempMed, Joshua Tree, and Dr. Furbaby. MYM Nutraceuticals is based in Vancouver, British Columbia.

Dr. Furbaby is the Company’s CBD line of products specifically for pets. HempMed is targeted at the dispensary market. Joshua Tree is targeted for the mainstream health market.

Currently, MYM Nutraceuticals is constructing three large-scale production facilities in Canada and Australia. These are the Northern Rivers Project; the Weedon Project; and the Laval Project. Upon completion, the total amount of greenhouse growing space will be more than 2.7 million square feet.

The Laval Project facility (Laval, Quebec) is 10,000 sq. ft. It will undergo expansion to 26,000 sq. ft. by 2019. The estimation is that the Laval Project will generate sales of $20 million by 2019.

The Northern Rivers Project (Casino, New South Wales, Australia) is a 1.2 million sq. ft. greenhouse project. The expectation is that the first crop will be planted in Q4 2018. The Northern Rivers Project facility is believed to be the Southern Hemisphere's largest purpose-built greenhouse, designed specifically to produce medical-grade cannabis.

The Weedon Project is in Weedon, Quebec. This Project will include a cannabis museum and a cannabis university for industry training. The Weedon Project has 1.5 million sq. ft. of greenhouse. MYM received approval and started Phase One construction of the Weedon production facility.

Additionality, the Company has its MJT Manufacturing Project (Toronto, Ontario). The 5,000 sq. ft. production facility is a GMP (Good Manufacturing Practice) certified, state-of-the-art extraction lab and production facility dedicated to industrial hemp processing (CBD). MYM Nutraceuticals has acquired an additional 18 percent of CannaCanada and the Weedon, Quebec project bringing its total ownership of the late stage ACMPR applicant, up to 93 percent.

Recently, MYM Nutraceuticals announced that it entered into a partnership with the University of Sherbrooke to study the medicinal and industrial uses of cannabis and hemp. Researchers at the University of Sherbrooke will work with an on-site coordinator to establish partnerships through targeting expertise in different faculties and training centers.

Mr. Rob Gietl, MYM Nutraceuticals’ Chief Executive Officer, said, "The signing of this partnership agreement with University of Sherbrooke furthers our goal to be at the forefront of cannabis plant research and development. Furthermore, I am delighted to see our company associated with a large Quebec university that has an outstanding reputation in research and innovation."

MYM Nutraceuticals, Inc. (MYMMF), closed Wednesday's trading session at $0.2862, up 34.8092%, on 199,386 volume with 93 trades. The average volume for the last 3 months is 170,242 and the stock's 52-week low/high is $0.177000001/$1.14999997.

chart

Wealthcraft Capital, Inc. (WCCP)

OTC Markets, MarketWatch, InvestorsHub, 4-Traders, Stockhouse, Simply Wall St, WalletInvestor, Penny Stock Hub, Penny Stock Tweets, Barchart, Stock Target Advisor, InvestorPlace, and Silicon Investor reported on Wealthcraft Capital, Inc. (WCCP),  and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Wealthcraft Capital, Inc. concentrates on the investment of capital in private companies, which are interested in expanding their business through gaining better access to capital, management consulting, as well as business development. Mr. Adam D. Sexton is the President and Chief Executive Officer (CEO) of the Company.

Mr. Sexton is an experienced business, entertainment, and digital media leader. He has wide-ranging experience launching and operating disruptive digital products and services for worldwide entertainment, technology industry leaders, as well as start-ups.

Wealthcraft Capital was previously known as Wealthcraft Systems, Inc. It changed its name to Wealthcraft Capital, Inc. in February of 2017. The Company’s shares trade on the OTC Markets Group’s OTCQB. Wealthcraft Capital has its corporate headquarters in Los Angeles, California.

Recently, WealthCraft Capital announced the acquisition of a majority interest in Geaux Industries in exchange for $1,000,000 of the Company’s common stock at market value. Geaux Industries is a provider of security services for commercial, retail and industrial customers, with customized services and special patrol methods applicable for the cannabis industry, 

Geaux Industries is licensed by the California Department of Consumer Affairs. For selected security operations, Geaux does business under the franchised name of Signal 88 Security. The exchange agreement provides for Wealthcraft Capital to acquire the minority interest, under certain terms and conditions.

Mr. Sexton said, “With the legalization of recreational cannabis in California on January 1, 2018, the Company believes that there is a significant market opportunity for Geaux Industries to be one of the leading providers of specialized security services.”

Geaux Industries will continue to address the market with inventive new technologies and services and creative business models for the traditional and non-traditional businesses.

At the closing, Wealthcraft Capital CEO, Adam Sexton, was appointed to fill a vacancy on the Board of Directors of Geaux Industries.

Wealthcraft Capital, Inc. (WCCP), closed Wednesday's trading session at $0.487, up 45.1824%, on 5,280 volume with 2 trades. The average volume for the last 3 months is 614 and the stock's 52-week low/high is $0.222000002/$0.899999976.

chart

Eco Science Solutions, Inc. (ESSI)

Wall Street Mover, ThePUMPTracker, DSR News, Real Pennies, Promotion Stock Secrets, TopPennyStockMovers, Wallstreetlivechat, and Pumps and Dumps reported earlier on Eco Science Solutions, Inc. (ESSI),  and we also report on the Company, here at the QualityStocks Daily Newsletter.

Eco Science Solutions, Inc. is an eco-technology Company with its corporate headquarters in Makawao, Hawaii. It provides solutions to the multi-billion-dollar health, wellness, and alternative medicine industry. Eco Science Solutions develops technical solutions - from enterprise software solutions, to consumer applications (apps) for daily use. These solutions energize enthusiasts in their pursuit and enjoyment of building eco-friendly businesses and living healthy lifestyles. Eco Science Solutions’ shares trade on the OTC Markets Group’s OTCQB.

Eco Science Solutions’ key services cover localized communications between consumers and business operators, social networking with like-minded enthusiasts, rich educational content, e-commerce, and fast delivery of products. These all cater to the health-and-wellness lifestyle.

The Company’s brands include Herbo, Fitrix, and pHion Balance. The Herbo app assists consumers in finding products and services that support the intake of alternative medicines for a more naturopathic lifestyle. Herbo has a database of greater than 14,000 alternative medicine locations and delivery services, doctors who provide evaluations, and local shops that sell relevant product.

The Fitrix app is a strong and flexible companion. Fitrix assists users’ in keeping track of their day-to-day fitness routines, dietary habits, and alternative medicine intake. Fitrix users can measure and track anything and everything concerning their health and wellness.

The Company’s pHion Balance underwent development to create nutritional supplements, which support and promote a healthy lifestyle. pHion Balance is centered on developing nutritional supplements that take the guesswork out of supplementing the body in the healthiest way.

Eco Science Solutions will continue to make investments in e-commerce and mobile applications that facilitate B2C (Business-to-Consumer) e-commerce opportunities.

 Eco Science Solutions' main projects have ocused on continued consumer and enterprise technology investment; continued product formulation and inventory build for distribution; and strategic acquisitions, which provide an accelerated time-frame to obtain market share.

In May of 2017, the Company announced that it signed a Sponsorship, Content Development, and Licensing agreement with Roaring Lion Tours, Inc.  Roaring Lion Tours develops inspirational and educational content that further promotes what it believes are the benefits of medical marijuana.  This agreement is to develop unique educational content that brings awareness and education to the alternative medicine category.

Eco Science Solutions, Inc. (ESSI), closed Wednesday's trading session at $0.016, up 45.4545%, on 2,500 volume with 3 trades. The average volume for the last 3 months is 7,674 and the stock's 52-week low/high is $0.201000005/$4.80000019.

chart

DSG Global,  Inc. (DSGT)

Epic Stock Picks, StockHideout, Stock Preacher, Penny Stocks Finder, SuperStockTips, Penny Stock Craze, SMS Penny Picks, eliteotc.com, WININGOTC, Wall Street Beauties, StockRockandRoll, The Observer, OTC Markets, PennyStockLocks.com, ResearchOTC,  InvestorSoup, and Beacon Equity Research reported previously on DSG Global,  Inc. (DSGT), and we report on the Company today, here at the QualityStocks Daily Newsletter.

DSG Global,  Inc. is a technology development company whose shares trade on the OTCQB. The Company engages in the design, manufacture, and marketing of fleet management solutions for the golf industry, and also commercial, government, and military applications worldwide.  DSG Global has historically concentrated on the golf industry. It has grown to become a leader in the Fleet Management category in the golf industry.  DSG Global is based in Surrey, British Columbia.

The Company provides patented electronic tracking systems and fleet management solutions to golf courses. These allow for remote management of the course's fleet of golf carts, turf equipment, as well as utility vehicles. DSG is best known for its advanced GPS TAG System for golf cart and turf equipment fleet management.  

DSG Global’s technology is installed in more than 10,000 vehicles on golf courses globally. The Company has an installed base of daily-fee and resort golf courses. Its cart-mounted Touch® display screens seamlessly deliver banner advertisements and full-motion videos while on the golf course.  

Fundamentally, golf course operators manage their fleet of golf carts, turf equipment, and utility vehicles remotely, using DSG Global’s SaaS  (Software as a Service)  technology and advanced GPS hardware. DSG has acquired Impact Tournament Solutions, along with Impact’s team of experts, to run the Tournament Solutions Division of DSG Global.  

DSG Global is currently branching into several new streams of revenue via programmatic advertising, licensing, and distribution.  Additionally, the Company is expanding into Commercial Fleet Management and Agricultural applications. It realized record European sales in 2017 because of new installation contracts with top rated European Golf Management businesses. Furthermore,  DSG Global is expanding into Raptor Single Rider Golf Car and 100E Fully Loaded Mullen Golf Cars, 2 and 4 seaters and Agricultural applications.

DSG Global has officially partnered with golf course video flyover company, STEADY MOTION. This is to bring the best interactive flyover videos to the golf sports industry. These flyover videos include professional, broadcast television quality audio narration, advanced color correction, and interactive course tours ready to be displayed on the DSG TOUCH screens and on golf course web portals.  

Recently, DSG Global announced that it is introducing to the global market the first ever Infinity 12" High Definition display. This display is equipped with streaming music, video, Bluetooth, stock market and sports scores, and the top-graded flyovers in the nation, credit card tap availability, dual speakers and Programmatic Advertising.

Furthermore, last month, DSG Global announced that it has taken first steps to move towards exploring potential use cases, which it has identified for blockchain and its related technologies to be applied to the golf industry.

Mr. Robert Silzer, DSG Global’s Chief Executive Officer, stated, "Blockchain will definitely change the golf industry and DSG plans to play a leading role to bring this change to fruition. I believe this technology will revitalize the golf industry. It can build a new bridge between golf and the millennials and raise new enthusiasm for the sport. It can release tremendous value that is currently untapped."

DSG Global,  Inc. (DSGT), closed Wednesday's trading session at $0.98, up 48.4848%, on 4,087 volume with 9 trades. The average volume for the last 3 months is 3,926 and the stock's 52-week low/high is $0.639999985/$10.3999996.

chart

Sauer Energy, Inc. (SENY)

Winston Small Cap, Shiznit Stocks, PennyStocks24, Fast Money Alerts, Penny Stock General, RockingPennyStocks, StockHideout, Investment U, DSR News, The Next Big Trade, Penny Stock Hub, BestDamnPennyStocks, and Stock Shock and Awe reported previously on Sauer Energy, Inc. (SENY), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Sauer Energy, Inc. is a technology developer and manufacturer. The Company is concentrating on the developing renewable energy market. It is the developer of the patented WindCharger™ brand vertical axis wind turbine (VAWT) and the manufacturer of the patented HelixWind® vertical axis wind turbine. Sauer Energy is uniting wind, solar, and storage together in harmony so that energy can be harnessed and processed to the greatest advantage. Sauer Energy’s head office and manufacturing facility is in Oxnard, California.

The Company is addressing worldwide energy through developing complete renewables packages by way of three energy sources that can help ensure the optimization of opportunities to capture the elements and produce electricity quicker, simultaneously, and individually. It created the WindCharger™ model to provide a better solution for the use of wind capture for residential or small building use. The WindCharger™ is one of its vital innovation priorities. Sauer Energy has several patents in place and more pending. 

The design of Helix vertical axis wind turbine systems is purposely to be pole mounted and can respond to the demand for applications that do not necessitate roof mounting. Sauer’s technology requires few parts. Therefore, it provides a new direction for wind capture, scales easily from residential to small community and up to large industrial scale. 

Sauer and Helix turbines underwent development to produce a quiet and low-impact technology with a high output of sustainable renewable energy. The focus of the WindCharger™ and Helix turbines has centered on patented disruptive technology, minimum impact on the environment, mounting flexibility, and versatility with highly efficient output.  

The Company’s WindRider® turbine has a new mount and its own proprietary system for on-grid or off-grid structures. The Company’s intention is to offer the patented helixical WindRider® model vertical axis wind turbine that uses the HelixWind technology.  

Sauer’s WindCutter turbine is a very powerful Darrieus design. The WindCutter has five airfoil blades that use the principle of lift to rotate the shaft. It is pole mounted. The Company’s WindCutter 2.5, VAWT design is the first model cleared for launch.

Recently, Sauer Energy had on view its WindCutter™ turbine solution at the Willow Springs International Motorsports Raceway, in Rosamond, California. With the installation completed and on display anyone could witness the WindCutter in operation as it produced power. The Company’s aim is to always improve technological advancements through finding new ways to make power more efficiently.

Mr. Dieter Sauer, Sauer Energy’s Chief Executive Officer and President said in late October, “What a milestone achievement for the SEI team as we enter a new chapter in our history.”

Sauer Energy, Inc. (SENY), closed Wednesday's trading session at $0.0082, up 29.1339%, on 20,100 volume with 3 trades. The average volume for the last 3 months is 53,757 and the stock's 52-week low/high is $0.003199999/$0.037.

chart

Enertopia Corp. (ENRT)

Penny Stock General, Shiznit Stocks, Cannabis Financial Network News, PennyStocks24, Fast Money Alerts, Stock Shock and Awe, Penny Champions, Equities.com, MassiveStockProfits, Wall Street Equities Research, Stockgoodies, GrowthPennyStocks, and Penny Dreamers reported earlier on Enertopia Corp. (ENRT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Enertopia Corp. is exploring a portfolio of three prospective lithium projects in the State of Nevada. Additionally, at the same time, the Company is working with water purification technology believed to be able to recover Lithium from brine solutions. Enertopia has its corporate office in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB.

Enertopia announced in April 2017 the formation of a Lithium business division for the exploration of Lithium. In May 2017, it closed the definitive agreement for the Lithium exploration project in Nevada.

In June 2017, Enertopia announced its Surface Exploration Program in Nevada. In Nevada, the Company has 2,560 acres of placer mining claims staked in Edwards, Smith and Big Smoky valleys.

The Central Nevada Lithium Brine Projects are proximal to an existing lithium mine. There is all weather access on paved roads and it is an ideal evaporation climate.

Genesis Water Technologies (GWT) is a partner of Enertopia. GWT is a manufacturer of advanced, innovative and sustainable treatment solutions for applications in process water, drinking water, water reuse and waste water for the energy, agriculture processing, industrial, municipal infrastructure, and building/hotel sectors.

Since September 2017, GWT has been evaluating data obtained from the first bench test results and other technical data provided by Enertopia to complete a larger and enhanced lithium recovery system. This $200,000 pre-paid second phase bench test is now complete. The second phase of the second bench test will use synthetic brine solutions, which will be created from the surface samples from the two bulk samples taken at Enertopia’s Clayton Valley project.

The next steps for the Company in 2018 are a bench test build out this month and preparation of synthetic brines in February. In March and April, bench testing of synthetic lithium brines will take place. In May will be final laboratory lithium recovery and Li2CO3 grade results.

Enertopia Corp. (ENRT), closed Wednesday's trading session at $0.023, up 48.1959%, on 15,000 volume with 2 trades. The average volume for the last 3 months is 85,263 and the stock's 52-week low/high is $0.011199999/$0.048999998.

chart

The QualityStocks Company Corner

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that R.J. Tesi, M.D., the company’s co-founder and CEO, presented at the Maxim Group’s conference on Alzheimer’s disease on June 26 in New York. During his presentation, Dr. Tesi addressed how INmune Bio’s drug candidate XPro1595 targets microglial activation and neuroinflammation to treat Alzheimer’s, which may be a key driver in the disease.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed Wednesday's trading session at $9.89, up 1.4359%, on 5,580 volume with 36 trades. The average volume for the last 3 months is 19,526 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW) was featured today in the 420 with CNW by CannabisNewsWire. Back in 2016, voters passed a measure to legalize recreational marijuana in Maine. Since then, residents have been waiting for the state government to draft and pass regulations which would operationalize recreational cannabis cultivation, manufacture and sales. Gov. Janet Mills has now signed the regulations and brings the long wait to an end.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Wednesday's trading session at $1.15, up 0.88%, on 11,100 volume with 9 trades. The average volume for the last 3 months is 47,624 and the stock's 52-week low/high is $1.05999994/$5.25.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of non-invasive electroceutical therapeutic devices, has appointed Dr. Steven Levin, M.D., a national leader in the field of pain management, to its scientific advisory board. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. He is also an assistant professor at Johns Hopkins School of Medicine’s Department of Anesthesiology.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed Wednesday's trading session at $0.01866, up 9.7647%, on 3,643,199 volume with 84 trades. The average volume for the last 3 months is 3,033,699 and the stock's 52-week low/high is $0.008999999/$0.066100001.

Recent News

chart

Trxade Group Inc. (TRXD)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (TRXD).

Trxade Group Inc. (OTCQB: TRXD), an integrated pharmaceutical logistical services company that offers a web-based e-hub buying platform for transactions between independent pharmacists and drug manufacturers, reported record Q1 2019 revenues. The company also reported (http://nnw.fm/znW3v) higher operating income, as it sees “continuing revenue growth and profitability in 2019.”

Trxade Group Inc. (TRXD) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade's overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company's pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, "E-Bay/Kayak-like" technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the "consumer side" of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called "Delivmeds" (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade's Managed Services Organization ("TrxadeMSO") enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient's information, thereby ensuring appropriate medication coverage based on the patient's location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade's fair online market platform targets the nation's retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE's programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks ("PAC") to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry.
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE's advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process.

Management Team

Trxade's management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary

Suren Ajjarapu has served as Trxade's chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer

Prashant Patel has served as Trxade's full-time president and COO, and as a director since the company's acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (TRXD), closed Wednesday's trading session at $0.55, even for the day, on 19,996 volume. The average volume for the last 3 months is 4,144 and the stock's 52-week low/high is $0.230000004/$0.75.

Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International, Inc. (NASDAQ: YGYI) was among 10 companies included in Horizons ETFs Management;s (Canada) ("Horizons ETFs") completed quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF ("HMMJ":TSX), the Horizons US Marijuana Index ETF ("HMUS":NEO) and the Horizons Emerging Marijuana Growers Index ETF ("HMJR":NEO). Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Many municipalities have been waiting on the state government to pass the regulatory framework before they can decide whether to opt in or out of the recreational industry. Now that the rules are out, the vast majority of municipalities in this category will make their position known by the time recreational sales officially begin.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Wednesday's trading session at $5.84, off by 1.1844%, on 29,295 volume with 269 trades. The average volume for the last 3 months is 106,347 and the stock's 52-week low/high is $3.56999993/$16.25.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings Inc. (CSE: TCAN) (OTC PINK: TCNAF) (FSE: TH8) ("TransCanna" or the "Company") will be providing a corporate update to its shareholders and investors on Wednesday, July 3rd at 1:15pm PST. The call in numbers are (US) 888-585-9008, (Canada) (888) 299-2873 and (Germany) 0 800 723 5123. The Conference room pin is 477 995 281. TransCanna management will discuss the progress of the proposed acquisitions involving GoodFellas, Soldaze, Lyfted Farms and Biovelle, as well as a general update on the licensing process for the 196,000 sq ft facility in Modesto, CA and the 10,000 sq ft facility in Adelanto, CA. Also today, the company was named among those included in the Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") quarterly rebalance.

TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) brings together a rapidly growing portfolio of cannabis and hemp-related brands and services, with a closed-loop ecosystem approach rooted squarely in the company’s ownership of a 196,000-square-foot, vertically integrated facility in California. The company has developed a two-year, four-phase plan aimed at developing proprietary brands and creating a self-contained ecosystem that ensures reliability, consistency, quality and scale.

Ecosystem

TransCanna’s cannabis facility in Modesto, California, is strategically located less than a three-hour drive from the majority of all major cities in the state. The tri-level building provides internal control of everything needed for the seed-to-sale cycle, from growing and manufacturing to extraction, bottling, transportation and distribution. The facility, which recently went through an US$8 million renovation, is upgraded with a premium quality HVAC system and highly insulated roof to help reduce power costs, which already are some of the lowest in California.

The company has set 2020 goal for implementation of its full-service software platform, 420 Global, which will interact with every aspect of production flow, business development and the sales process.

Growing Portfolio

Acquisitions slated to be completed in June include Goodfellas Group LLC, a full-service advertising and marketing agency for the U.S. cannabis and hemp industries. Under the deal, TransCanna will also be acquiring Daily Cannabis Goods, a pre-rolled brand with nominal start-up costs and superior SKU velocity with cannabis products available at more than 30 dispensaries throughout California.

On Deck

The company has moved to acquire organic hemp-infused CBD coconut oil Biovelle (www.Biovelle.com). Biovelle is non-GMO, vegan and gluten free, with coconut sourced from plantations in the Philippines and American grown hemp from farms in Colorado.

TransCanna has also moved to further secure a growing foothold in cannabis edibles via a non-binding letter of intent with Persuasion Brewing Co., located near the company’s flagship facility in Modesto. The goal is to establish a Persuasion Brewing division at the main facility, which will produce a variety of different CBD infusion non-alcoholic beers.

Similarly, the company has recently executed a non-binding LOI with SolDaze (Tres Ojos Naturals, LLC) to gobble up the branding asset package of this California manufacturer of cannabis-infused fruit snacks (www.soldazesnacks.com).

Management

TransCanna’s management team consists of seasoned agriculture and consumer goods-oriented veterans.

Director, CEO and Chairman James Pakulis has 30 years of experience working with public and private entrepreneurial companies in a variety of emerging sectors. He has been on the front lines of the California cannabis industry for nearly a decade. He was CEO and chairman in 2010 of General Cannabis, Inc., which wholly owned the popular Weedmaps brand. Pakulis oversaw the growth of General Cannabis from pre-embryonic stages to over $16 million in revenue in less than two years, reaching a market cap of approximately $480 million.

Director and President Arni Johannson brings over 30 years of investing experience in the Canadian capital markets. He has built and or funded over 50 startups from around the world. He is president of Canadian Nexus Ventures and has been instrumental in providing guidance to pre- and post IPO companies, as well as guidance and oversight for corporate governance.

Stephen Giblin, board director, is an accomplished leader in the global hospitality, technology and real estate industries with a demonstrated track record of value creation. Juan Pablo Flores, independent director, is an attorney with more than 25 years of legal experience with a strong background in municipal, government, real estate, corporate and general civil law litigation.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

TransCanna Holdings Inc. (CSE: TCAN), closed Wednesday's trading session at $3.80, off by 8.43%, on 342,412 volume with 707 trades. The average volume for the last 3 months is 137,267 and the stock's 52-week low/high is $0.76999998/$7.78999996.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was featured today in a video report from BTV News examining how the company is all about organic. http://ibn.fm/NnW52.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Wednesday's trading session at $2.395, off by 1.8443%, on 206,163 volume with 426 trades. The average volume for the last 3 months is 645,907 and the stock's 52-week low/high is $1.60699999/$7.89379978.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Vancouver-based company Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) was recently featured alongside various cannabis companies including Burkelman, Vertly and Cannuka in an article on Buzzfeed.com titled, ‘Here's Why You Should Buy CBD For Everyone You Know This Holiday’ authored by Jessica Probus. To view the full article, visit: http://nnw.fm/fr9Ie.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed Wednesday's trading session at $0.485, off by 3.0194%, on 7,051 volume with 12 trades. The average volume for the last 3 months is 23,369 and the stock's 52-week low/high is $0.009999999/$1.12999999.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P), a leading Canadian investment company pursuing specialty investment opportunities in the burgeoning cannabis industry (among others), recently announced that it has now completed the purchase of a 49 percent interest in Cannova Medical Ltd., totaling 2,260,500 shares. Nabis retains the option to acquire the remaining 51 percent interest in Cannova.

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Wednesday's trading session at $0.269, off by 7.8136%, on 18,352 volume with 24 trades. The average volume for the last 3 months is 65,945 and the stock's 52-week low/high is $0.212999999/$0.791499972.

Recent News

chart

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)

The QualityStocks Daily Newsletter would like to spotlight Therma Bright, Inc. (OTC: THRBF).

Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that further to its press releases on October 11th and December 17th, 2018 and March 28th, 2019 that the Company continues testing of the TherOZap™ technology against the Zika virus upon the advice of one of the top research laboratories in Canada working with Therma Bright. A number of additional testing parameters have been added to the testing regime and, as previously reported, the aim of the research lab is to produce statistically relevant results. Therma Bright will report further information as it becomes available.

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

Products

The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.

Cannabis

Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.

Management

Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

Therma Bright, Inc. (OTC: THRBF), closed Wednesday's trading session at $0.022, even for the day, on 250 volume. The average volume for the last 3 months is 3 and the stock's 52-week low/high is $0.009899999/$0.028999999.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (MCOA) today announced that the Company’s Board of Directors and Stockholders have approved a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-60. The decision was made at a Special Meeting of Stockholders held on July 1, 2019. Also today, the company was highlighted in the Venture Breakfast Bits, by 24/7 Market News

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed Wednesday's trading session at $0.0087, off by 18.3099%, on 35,051,404 volume with 629 trades. The average volume for the last 3 months is 7,815,828 and the stock's 52-week low/high is $0.008/$0.039299998.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed Wednesday's trading session at $0.48, up 4.3478%, on 127,896 volume with 64 trades. The average volume for the last 3 months is 223,106 and the stock's 52-week low/high is $0.330000013/$1.52999997.

Recent News

chart

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Wednesday's trading session at $6.52, up 3.6566%, on 892,445 volume with 2,613 trades. The average volume for the last 3 months is 935,175 and the stock's 52-week low/high is $2.97000002/$8.43999958.

Recent News

chart

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF)

The QualityStocks Daily Newsletter would like to spotlight Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF).

Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF), an investment company focused on the U.S. and international cannabis sectors, provides turnkey solutions for the regulated cannabis industry. The company leverages managements' expertise and decades of experience in the cannabis industry to acquire and develop vertically integrated cannabis assets. Chemistree recently closed on a purchase of prospective cannabis cultivation property in California, made a first investment in the Canadian cannabis industry, owns assets in the State of Washington used to operate an established retail cannabis brand, and has an active pipeline of assets in place to grow its portfolio.

Chemistree offers industry leading expertise across all areas the cannabis business and in its growth as a public or private company.

  • Investment and funding for rapid growth
  • Vertical integration solutions
  • Construction, design and/or optimization of indoor or outdoor cultivation facilities
  • Reputation management & influencer outreach
  • Branding and Packaging
  • Social Media and Media outreach

With the marketing of cannabis companies and their products in its infancy, the company believes the industry offers tremendous opportunity for growth in the U.S. and abroad. Chemistree initially targeted the Pacific Northwest for investment and, following its recent California property purchase, expects to expand vertically across the United States in areas where it has a competitive business advantage.

Through its wholly owned CHM Desert LLC subsidiary, Chemistree owns 9.55 acres of undeveloped land in Desert Hot Springs, California. The property is zoned as Light Industrial Lands Designated for Marijuana Cultivation, and local zoning ordinances allow as a conditional use the location of up to three onsite cannabis cultivation buildings of 68,000 square feet each, along with support space that would support production of 55,000 pounds/year.

Through its wholly owned Chemistree Washington Ltd. subsidiary, Chemistree acquired physical assets used in the cultivation, production and distribution of cannabis. The Washington assets are currently under lease to Sugarleaf Farm LLC, which operates the Sugarleaf brand of retail cannabis products in the State of Washington. Sugarleaf Farm is a Tier 3 cannabis producer and processor whose products are sold in about 125 retail outlets. Chemistree has indicated the relationship with Sugarleaf may provide the company with additional opportunities to become involved in the marketing of Sugarleaf products.

Chemistree funded these acquisitions and investments with the proceeds of two non-brokered private placement financings completed earlier this year under the regulations of the Canadian Securities Exchange, totaling CAD$4.5 million. In conjunction with the private placements, the company was granted approval by the CSE for a change of business to become an Investment Issuer. This funding is expected to provide the company "maximum flexibility to take advantage of the numerous opportunities available in the cannabis industry in Canada and the U.S."

Chemistree also has a strategic investment in Pasha Brands Ltd., a British Columbia based cannabis company with multiple internationally recognized brands. Pasha has a proven history in cannabis retailing and its proposed Licensed Processing (LP) facility on Vancouver Island is in the final stage of the application for government approval. The LP facility is expected to assist in licensing selected craft growers of cannabis and expanding the distribution of locally grown product. The investment represents less than 10% of Chemistree's working capital.

Company Chairman Justin Chorbajian is co-owner of the largest chain of privately owned hydroponic retail shops in Canada. He also cofounded a group of companies that manufacture and distribute hydroponic equipment. He is a frequent contributor to Growing Exposed, the leading video series dedicated to cannabis cultivation. Company President Karl Kottmeier is a former investment advisor with 20 years of experience listing, financing and administering companies on the Toronto Stock Exchange and TSX Venture Exchange. He has raised more than $150 million in equity capital for ventures. Chemistree CFO Doug Ford has been general manager of Dockside Capital Group Inc., a private merchant banking and venture capital firm serving emerging growth companies. Sheldon Aberman, the most recent member of the Board, has managed, designed and created industry leading grow room designs around the world. Additionally, he has built several leading brands such as Frost Box and Black Label and is an expert in the accessory market (vape pens, silicon mats and extraction tools etc.).

Data firm Statista has forecast the U.S. legal cannabis market will be worth more than $24 billion by 2025. New Frontier Data, which focuses exclusively on the cannabis industry, projects the value of the Canadian domestic cannabis market that same year at CAD$9.2 billion.

Chemistree Technology Inc. (CHMJF), closed Wednesday's trading session at $0.279, up 4.9661%, on 13,907 volume with 7 trades. The average volume for the last 3 months is 115,146 and the stock's 52-week low/high is $0.206484004/$0.605000019.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.